Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Dimarchi

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Journal of Diabetes Science and Technology|December 7, 2010
In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effectW Kenneth Ward, Ryan G Massoud, Cory J Szybala, et al.
Cardiovascular Diabetology|August 17, 2023
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic diseaseStephan Sachs, Anna Götz, Brian Finan, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2025
Sustained Action of Imapextide, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy VolunteersElisa Fabbrini, Anastasiya Koshkina, Michael Hackett, et al.
Journal of Medicinal Chemistry|May 15, 2020
Addition of Sialic Acid to Insulin Confers Superior Physical Properties and BioequivalenceDaniel E K Kabotso, David Smiley, John P Mayer, et al.
Molecular Microbiology|April 15, 2015
A new quorum-sensing system (TprA/PhrA) for Streptococcus pneumoniae D39 that regulates a lantibiotic biosynthesis gene clusterSharon E Hoover, Amilcar J Perez, Ho-Ching T Tsui, et al.
ACS Pharmacology & Translational Science|October 19, 2020
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21Jia Pan, Sebastian D Parlee, Florence M Brunel, et al.
Cardiovascular Diabetology|September 12, 2024
Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic diseaseStephan Sachs, Anna Götz, Brian Finan, et al.
Journal of Medicinal Chemistry|April 6, 2021
Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full AntagonistsBin Yang, Vasily M Gelfanov, Diego Perez-Tilve, et al.
Journal of Molecular Biology|January 29, 2013
Allosteric inhibition of a zinc-sensing transcriptional repressor: insights into the arsenic repressor (ArsR) familyGregory C Campanello, Zhen Ma, Nicholas E Grossoehme, et al.
RSC Chemical Biology|August 2, 2024
Toward once-monthly insulin therapy <i>via</i> synergy in two pharmacokinetic protractors: Fc-conjugation and fatty acid acylationAlexander N Zaykov, Vasily M Gelfanov, Tina M Tagmose, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Journal of Diabetes Science and Technology|December 7, 2010
In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effectW Kenneth Ward, Ryan G Massoud, Cory J Szybala, et al.
Cardiovascular Diabetology|August 17, 2023
GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic diseaseStephan Sachs, Anna Götz, Brian Finan, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2025
Sustained Action of Imapextide, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy VolunteersElisa Fabbrini, Anastasiya Koshkina, Michael Hackett, et al.
Journal of Medicinal Chemistry|May 15, 2020
Addition of Sialic Acid to Insulin Confers Superior Physical Properties and BioequivalenceDaniel E K Kabotso, David Smiley, John P Mayer, et al.
Molecular Microbiology|April 15, 2015
A new quorum-sensing system (TprA/PhrA) for Streptococcus pneumoniae D39 that regulates a lantibiotic biosynthesis gene clusterSharon E Hoover, Amilcar J Perez, Ho-Ching T Tsui, et al.
ACS Pharmacology & Translational Science|October 19, 2020
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21Jia Pan, Sebastian D Parlee, Florence M Brunel, et al.
Cardiovascular Diabetology|September 12, 2024
Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic diseaseStephan Sachs, Anna Götz, Brian Finan, et al.
Journal of Medicinal Chemistry|April 6, 2021
Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full AntagonistsBin Yang, Vasily M Gelfanov, Diego Perez-Tilve, et al.
Journal of Molecular Biology|January 29, 2013
Allosteric inhibition of a zinc-sensing transcriptional repressor: insights into the arsenic repressor (ArsR) familyGregory C Campanello, Zhen Ma, Nicholas E Grossoehme, et al.
RSC Chemical Biology|August 2, 2024
Toward once-monthly insulin therapy <i>via</i> synergy in two pharmacokinetic protractors: Fc-conjugation and fatty acid acylationAlexander N Zaykov, Vasily M Gelfanov, Tina M Tagmose, et al.
Pageof 13